Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research

Key Points

• Amicus Therapeutics has been upgraded to a "strong-buy" rating by Zacks Research, with projected earnings estimates indicating growth through 2027.
• Despite a mix of ratings from various firms, the consensus stands at a "Moderate Buy" with a target price set at $15.78.
• Notably, several large investors have significantly increased their stakes in Amicus Therapeutics, signaling a positive outlook among institutional investors.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Monday,Zacks.com reports. Zacks Research also issued estimates for Amicus Therapeutics' Q3 2026 earnings at $0.12 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.16 EPS and FY2027 earnings at $0.60 EPS.

A number of other research firms have also recently weighed in on FOLD. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, September 20th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Amicus Therapeutics in a research note on Saturday, September 27th. Needham & Company LLC upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. Finally, Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.78.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $8.16 on Monday. The stock has a market cap of $2.52 billion, a PE ratio of -67.99 and a beta of 0.56. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The business has a 50 day moving average price of $7.62 and a two-hundred day moving average price of $6.90. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92.

Hedge Funds Weigh In On Amicus Therapeutics

Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,007 shares during the period. Rhumbline Advisers increased its position in Amicus Therapeutics by 6.9% in the first quarter. Rhumbline Advisers now owns 440,351 shares of the biopharmaceutical company's stock worth $3,593,000 after buying an additional 28,383 shares during the period. SG Americas Securities LLC increased its position in Amicus Therapeutics by 137.6% in the first quarter. SG Americas Securities LLC now owns 100,993 shares of the biopharmaceutical company's stock worth $824,000 after buying an additional 58,496 shares during the period. Diversified Trust Co increased its position in Amicus Therapeutics by 2.2% in the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock worth $682,000 after buying an additional 1,784 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Amicus Therapeutics by 53.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock worth $195,000 after buying an additional 8,567 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.